What is the appropriate evaluation and management of chronic gastritis, including assessment for Helicobacter pylori, NSAID/alcohol use, alarm features, and treatment options?

Chronic Gastritis: Evaluation and Management

Initial Risk Stratification by Age and Alarm Features

Patients ≥55 years old or any patient with alarm features (anemia, unintentional weight loss, dysphagia, palpable abdominal mass, malabsorption, gastrointestinal bleeding, or family history of gastric cancer) require immediate upper endoscopy with biopsy for H. pylori testing, as the risk of gastric malignancy rises sharply after age 45–55. 1, 2, 3

Alarm Features Requiring Urgent Endoscopy (Any Age)

• Anemia – may signal complicated peptic ulcer disease or gastric malignancy 2
• Unintentional weight loss – warrants immediate specialist referral 2, 3
• Progressive dysphagia – requires urgent evaluation 2, 3
• Palpable abdominal mass – mandates endoscopy regardless of age 2, 3
• Evidence of gastrointestinal bleeding – requires urgent endoscopy 2
• Family history of gastric cancer – even in patients <45 years old, this represents significant risk 2, 3
• Malabsorption symptoms – may indicate advanced disease 2

Management Algorithm for Patients <55 Years Without Alarm Features

Step 1: Assess NSAID/Alcohol Use and Reflux Symptoms

If the patient is taking NSAIDs, discontinue them first; if symptoms resolve, no further evaluation is needed. 1, 4

• For patients with predominant heartburn or acid regurgitation occurring more than once weekly, manage as GERD with PPI therapy rather than pursuing dyspepsia evaluation 1
• Consider switching NSAID users to alternative agents or adding PPI gastroprotection 1

Step 2: Test-and-Treat Strategy for H. pylori

For patients <55 years without alarm features, NSAID use, or predominant reflux symptoms, implement the "test-and-treat" approach using non-invasive testing, which is equally effective and more cost-efficient than prompt endoscopy (reducing costs from £404 to £206 per patient annually and cutting endoscopy workload by 62%). 1, 2, 3

Recommended Non-Invasive Tests (in order of preference):

1. ¹³C-urea breath test – highest accuracy 1, 2, 3
2. Stool antigen test – 90–95% accuracy 2, 3
3. Laboratory serology – only if locally validated; avoid rapid office serological tests due to variable sensitivity 2, 3

Critical testing precaution: Stop antibiotics, bismuth, or PPIs at least 2 weeks before testing to avoid false-negative results 2, 5

Step 3: Treatment Based on H. pylori Status

If H. pylori Positive:

Prescribe triple therapy eradication regimen: amoxicillin 1 gram + clarithromycin 500 mg + PPI (omeprazole 20 mg or equivalent) twice daily for 14 days. 2, 3, 6, 7

• Alternative regimen: Sequential therapy with PPI + amoxicillin for 5 days, followed by PPI + clarithromycin + tinidazole for 5 days 4
• Take PPIs at the start of meals to minimize gastrointestinal intolerance 2
• Eradication provides long-term symptom relief in 1 out of 12 patients with functional dyspepsia, but should still be pursued as preventive medicine to reduce risk of peptic ulcer disease, atrophic gastritis, and gastric cancer 2, 3

Confirmation of eradication: Test at least 4 weeks after treatment cessation using breath test or stool antigen test (not serology) in high-risk patients (complicated peptic ulcer disease, gastric ulcer, known gastric ulcer history, family history of gastric cancer, or atrophic gastritis/intestinal metaplasia) 2, 3, 5

• Routine confirmation testing is not required in low-risk patients 3
• If symptoms persist after confirmed eradication, treat based on predominant symptom pattern with full-dose PPI therapy for epigastric pain 2

If H. pylori Negative:

Prescribe empirical PPI therapy (omeprazole 20 mg once daily or equivalent) for 4–8 weeks, taken 30–60 minutes before meals. 1, 3

• PPIs are the drug class of choice for acid suppression; H2-receptor antagonists are inadequate for gastroprotection in high-risk patients 1, 2
• Use the lowest effective PPI dose 3

Step 4: Management of Persistent Symptoms

Endoscopy is indicated only if symptoms persist despite H. pylori eradication (when applicable) and empirical PPI therapy, or if alarm features develop at any point. 1, 3

• Endoscopy adds little diagnostic value in young patients without alarm features who fail initial therapy, as the probability of finding relevant organic disease is very low 1
• Most patients with dyspepsia undergoing endoscopy are found to have functional dyspepsia, not organic findings 5
• Reevaluate symptoms and diagnosis before proceeding to endoscopy 1

Special Considerations for High-Risk Populations

Screening Recommendations for Asymptomatic High-Risk Individuals

Opportunistic screening is recommended for persons in high-risk ethnic groups (Asian, Hispanic, Black, Native American), recent immigrants from high-incidence countries (Eastern Europe, Andean Latin America, East Asia), and those with family history of gastric cancer or known household H. pylori infection, ideally between ages 20–40 years before development of precancerous lesions. 2

• First-degree relatives of H. pylori-positive individuals have 2–3 fold greater infection likelihood; screen adult household members when a case is identified 2
• Low socioeconomic status during childhood, household crowding, poor sanitation, and lack of clean water are powerful predictors of infection 2

NSAID Users with H. pylori Infection

In NSAID users with H. pylori infection, eradication reduces peptic ulcer risk by 50% and should be pursued before initiating chronic NSAID therapy. 2

• H. pylori gastritis increases the likelihood of developing dyspeptic symptoms on NSAID therapy 8
• Ulcers are more likely to develop during NSAID therapy in those infected with H. pylori; eradication reduces ulcer recurrence with continued NSAID use 8
• The majority of peptic ulcers are associated with H. pylori irrespective of NSAID use, though H. pylori-negative ulceration is more frequent in NSAID users 9

Endoscopic Findings and Biopsy Protocol

When endoscopy is performed, the following findings may be observed:

• Chronic gastritis – no pathognomonic endoscopic sign exists; definitive diagnosis requires rapid urease test, histology with special staining, or non-invasive tests 5
• Antral-predominant gastritis – associated with duodenal ulcer diathesis 5
• Corpus-predominant gastritis with multifocal atrophy – increased risk of gastric ulcer and carcinoma 5
• Pan-gastritis – high risk for serious disease progression 5
• Atrophic gastritis with or without intestinal metaplasia – premalignant condition requiring biopsy and follow-up 5
• Peptic ulcers – H. pylori responsible for >95% of duodenal ulcers and most gastric ulcers not related to NSAID use 5

During endoscopy, obtain biopsies for rapid urease test (RUT) and histology with immunohistochemical staining if doubt exists; culture may be important for detecting antibiotic resistance. 5

• Patients with known gastric ulcers require repeat endoscopy with biopsy until healed because malignancy may be present 5
• Discontinue antibiotics, bismuth, or PPIs before endoscopy to reduce false-negative results 5

Common Pitfalls to Avoid

• Do not rely on rapid office serological tests – they have variable sensitivity and specificity compared to breath or stool tests 2, 3
• Do not use H2-receptor antagonists for gastroprotection in high-risk patients; they are inadequate compared to PPIs 2
• Do not perform routine confirmation testing in low-risk patients after eradication therapy; reserve for high-risk conditions 3
• Do not proceed to endoscopy prematurely in young patients without alarm features; the test-and-treat strategy is more cost-effective 1, 3
• Do not forget to stop PPIs, antibiotics, and bismuth at least 2 weeks before H. pylori testing to avoid false negatives 2, 5